TrialClinical cancer research : an official journal of the American Association for Cancer Research2013

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

Federica Catalanotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.